1-[1-(naphth-2-yl)-cyclobutyl]butylamine.hydrochloride | 84484-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[1-(naphth-2-yl)-cyclobutyl]butylamine.hydrochloride
• 英文别名: 1-(1-Naphthalen-2-ylcyclobutyl)butan-1-amine;hydrochloride
• CAS: 84484-87-7
• 化学式: C₁₈H₂₃N*ClH
• 分子量: 289.848
• InChiKey: WWZWFVQBGDMZME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.81
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [DE] VERWENDUNG ARYLSUBSTITUIERTER CYCLOBUTYLALKYLAMINE ZUR BEHANDLUNG DER FETTLEIBIGKEIT<br/>[EN] USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY<br/>[FR] UTILISATION DE CYCLOBUTYLALKYLAMINES SUBSTITUEES PAR ARYLE POUR LE TRAITEMENT DE L'OBESITE
  申请人：KNOLL AG

  公开号：WO1996038134A1

  公开（公告）日：1996-12-05

  (DE) Verwendung von arylsubstituierten Cyclobutylalkylaminen und deren pharmazeutisch verträglichen Salze zur Behandlung der Fettleibigkeit und deren Begleiterkrankungen.(EN) The use of aryl substituted cyclobutyl alkyl amines and their pharmaceutically acceptable salts for the treatment of obesity and its accompanying conditions.(FR) Utilisation de cyclobutylalkylamines substituées par aryle et de leurs sels pharmaco-compatibles pour le traitement de l'obésité et de ses maladies associées.

  应用萘系环丙烷胺类药物及其药用上可接受的盐类，用于治疗肥胖及其并发症。（德语原文：Verwendung von arylsubstituierten Cyclobutylalkylaminen und deren pharmazeutisch verträglichen Salze zur Behandlung der Fettleibigkeit und deren Begleiterkrankheiten. 英文译文：The use of aryl substituted cyclobutyl alkyl amines and their pharmaceutically acceptable salts for the treatment of obesity and its accompanying conditions. 法语译文：Utilisation de cyclobutylalkylamines substituées par aryle et de leurs sels pharmaco-compatibles pour le traitement de l'obésité et de ses maladies associées.）
• VERWENDUNG ARYLSUBSTITUIERTER CYCLOBUTYLALKYLAMINE ZUR BEHANDLUNG DER FETTLEIBIGKEIT
  申请人：Knoll AG

  公开号：EP0828484A1

  公开（公告）日：1998-03-18
• SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP3082782A1

  公开（公告）日：2016-10-26
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.